A5047102325- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Transplantation: Methods and Outcomes
- Bone and Joint Diseases
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Bone health and treatments
- Cancer Genomics and Diagnostics
- RNA Interference and Gene Delivery
- Immune Cell Function and Interaction
- Epigenetics and DNA Methylation
- Bone health and osteoporosis research
- Hemoglobinopathies and Related Disorders
- Adolescent and Pediatric Healthcare
- Cell Adhesion Molecules Research
- Chemokine receptors and signaling
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Pharmaceutical studies and practices
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Immune Response and Inflammation
- Neutropenia and Cancer Infections
Princess Máxima Center
2020-2024
Stichting Kinderoncologie Nederland
2015-2024
Erasmus University Rotterdam
2003
Erasmus MC
2003
Rotterdam University of Applied Sciences
1999-2002
We studied cumulative incidence, risk factors, therapeutic strategies, and outcome of symptomatic osteonecrosis in pediatric patients with acute lymphoblastic leukemia (ALL).Cumulative incidence was assessed prospectively 694 treated the dexamethasone-based Dutch Child Oncology Group-ALL9 protocol. Osteonecrosis defined by development symptoms (National Cancer Institute grade 2 to 4) during treatment or within 1 year after discontinuation, confirmed magnetic resonance imaging. evaluated...
RAS pathway mutations have been linked to relapse and chemotherapy resistance in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, comprehensive data on the frequency prognostic value of subclonal well-defined subgroups using highly sensitive quantitative methods are lacking. Targeted deep sequencing 13 genes was performed 461 BCP-ALL cases at initial diagnosis 19 diagnosis-relapse pairs. Mutations were present 44.2% patients, with 24.1% carrying a clonal mutation....
PURPOSE In the DCOG ALL-11 protocol, polyethylene glycol–conjugated Escherichia coli asparaginase (PEGasparaginase) and Erwinia treatment of pediatric acute lymphoblastic leukemia are individualized with therapeutic drug monitoring (TDM). The efficacy TDM its effect on asparaginase-associated toxicity reported. PATIENTS AND METHODS After induction 3 fixed intravenous doses 1,500 IU/m 2 PEGasparaginase, medium-risk patients (n = 243) received 14 that targeted trough levels 100-250 IU/L,...
A previous study by the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) on childhood
Approximately 15% of pediatric B cell precursor acute lymphoblastic leukemia (BCP-ALL) is characterized by gene expression similar to that BCR-ABL1-positive disease and unfavorable prognosis. This BCR-ABL1-like subtype shows a high frequency B-cell development aberrations tyrosine kinase-activating lesions. To evaluate the clinical significance kinase fusions in children with BCP-ALL, we studied recently identified fusions, associated genetic features, prognosis representative Dutch/German...
ABL-class fusion genes other than BCR-ABL1 have been identified in approximately 3% of children with newly diagnosed acute lymphocytic leukaemia, and studies suggest that leukaemic cells carrying fusions can be targeted successfully by tyrosine-kinase inhibitors. We aimed to establish the baseline characteristics outcomes paediatric patients B-cell leukaemia pre-tyrosine-kinase inhibitor era.This multicentre, retrospective, cohort study included (aged 1-18 years) (ABL1 fusion-positive, ABL2...
Acute lymphoblastic leukemia (ALL) with fusions of ABL-class tyrosine kinase genes other than BCR::ABL1 occurs in ∼3% children ALL. The involved this BCR::ABL1-like (Ph-like) subtype include ABL1, PDGFRB, ABL2, and CSF1R, each which has up to 10 described partner genes. ALL resembles BCR::ABL1-positive a similar gene expression profile, poor response chemotherapy, sensitivity inhibitors (TKIs). There is lack comprehensive data regarding TKI the heterogeneous group We observed variability...
We prospectively studied the incidence and clinical course of hypertriglyceridemia hypercholesterolemia during very prolonged use asparaginase in relation to levels activity children with acute lymphoblastic leukemia. also evaluated pancreatitis, thrombosis, hyperammonemia central neurotoxicity their association levels. Eighty-nine patients were treated according Dutch Childhood Oncology Group Acute Lymphoblastic Leukemia 10 medium-risk intensification protocol, which includes 15 doses...
Venous thromboembolism (VTE) is relatively common in children with acute lymphoblastic leukemia (ALL). Thrombotic risk factors ALL are asparaginase and steroids. However, within the populations treated on same regimen, it less clear which other play a role. Furthermore, few data available effect of VTE outcomes.In 778 (1-18 years) newly diagnosed precursor-B-lineage or T-lineage ALL, Dutch Childhood Oncology Group (DCOG) ALL-10 protocol Netherlands (October 2004 to April 2013), we conducted...
Abstract Pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is associated with a high frequency of copy number alterations (CNAs) in IKZF1 , EBF1 PAX5 CDKN2A/B RB1 BTG1 ETV6 and/or the PAR1 region (henceforth: development genes). We aimed to gain insight association between CNAs these genes, clinical outcome parameters, and cellular drug resistance. 71% newly diagnosed pediatric BCP-ALL cases harbored one or more genes. The distribution relevance was highly subtype-dependent....
Childhood cancer survivors are confronted with various chronic health conditions like therapy-related malignancies. However, it is unclear how exposure to chemotherapy contributes the mutation burden and clonal composition of healthy tissues early in life. Here, we studied accumulation hematopoietic stem progenitor cells (HSPC) before after treatment 24 children. Of these children, 19 developed myeloid neoplasms (t-MN). Posttreatment HSPCs had an average increase comparable what...
Abstract A comprehensive international consensus on the cytogenetic risk-group stratification of KMT2A-rearranged (KMT2A-r) pediatric acute myeloid leukemia (AML) is lacking. This retrospective (2005-2016) International Berlin-Frankfurt-Münster Study Group study 1256 children with KMT2A-r AML aims to validate prognostic value established recurring KMT2A fusions and additional aberrations (ACAs) define additional, ACAs, evaluating their relevance. Compared our previous study, 3 groups were...
Abstract Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand and genetic features of this found age drivers were significantly associated outcome. diagnosed in under 3 years was extremely high-risk enriched for alterations that result both LMO2 activation STAG2 inactivation. Mechanistically, using patient samples isogenic cell lines, we show...
Body mass index and change in body during treatment may influence outcome of pediatric patients with acute lymphoblastic leukemia. However, previous studies leukemia reported contradictory results. We prospectively collected data on composition from a cohort newly diagnosed Dutch (n=762, age 2–17 years). Patients were treated 1997–2004 the median follow-up was 9 years (range, 0–10). at diagnosis expressed as age- gender-matched standard deviation scores basis these categorized being...
// Elisabeth M.P. Steeghs 1, * , Isabel S. Jerchel Willemieke de Goffau-Nobel 1 Alex Q. Hoogkamer Judith M. Boer 6 Aurélie Boeree Cesca van Ven Marco J. Koudijs 2, 3 Nicolle J.M. Besselink Hester A. Groot-Kruseman 4 Christian Michel Zwaan Martin Horstmann 5 Rob Pieters 4, and Monique L. den Department of Pediatric Oncology/Hematology, Erasmus Medical Centre – Sophia Children’s Hospital, Rotterdam, The Netherlands 2 for Personalized Cancer Treatment, Utrecht, Genetics,...
Abstract We assessed the epidemiologic progress against childhood and adolescent acute lymphoblastic leukaemia (ALL) in Netherlands over a 26 year period. ALL patients <18 years were selected from Cancer Registry Dutch Childhood Oncology Group. Trend analyses performed time by age group subtype. Between 1990 2015, 2997 diagnosed, i.e. 115 (range 87–147) per year. Overall incidence remained stable at 37 million children, despite increases for B-cell precursor (BCP-ALL) 10–14 (AAPC + 1.4%,...
The primary objective of this randomized study was to determine whether a continuous dosing schedule (without the asparaginase-free interval) would result in less hypersensitivity reactions PEGasparaginase (PEGasp) compared with standard noncontinuous schedule.
Abstract Background We report on the treatment of children and adolescents with acute lymphoblastic leukemia (ALL) in first relapse. The protocol focused on: (1) Intensive chemotherapy preceding allogeneic stem cell transplantation (SCT) early bone marrow relapse; (2) Rotational late relapse, without donor; (3) Postponement cerebro‐spinal irradiation isolated CNS (4) Treatment very relapse only. Methods From January 1999 until July 2006 all 158 Dutch pediatric patients ALL were recorded....
A better understanding of lymphocyte dynamics during current treatment regimens in pediatric AML is urgently needed to understand whether the application bispecific T-cell-engagers (BiTEs) periods low tumor burden could be a viable strategy. In this study, we found that induction 1, comprising mitoxantrone-etoposide-cytarabine nearly all patients (as part NOPHO-DBH AML-2012 protocol), led preserved or increased relative abundances alongside marked blast reduction most cases. This was...